FDA’s Untitled Letter Posting Driven By ‘Significant Public Interest,’ Not Stock Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Response to congressional inquiry also notes that FDA's policy is not to make policy in untitled letters.
You may also be interested in...
US FDA Compliance Strategy: Meetings Replace Some Untitled Letters
FDA’s CDER compliance office may use in-person meetings instead of untitled letters to avoid bureaucratic delays when raising minor concerns.
FDA Policy Power Challenged In House Questions On Untitled Letters
Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.